← Back to Companies

Aeovian Pharmaceuticals

Developing novel and highly selective therapeutics modulating the mTORC1 pathway.

Investors
1
Categories
therapeutics, biotech, longevity-research

Notes

Developing novel and highly selective therapeutics modulating the mTORC1 pathway. Portfolio company of Apollo Health Ventures.

Additional Research Findings

  • mTORC1 pathway modulation
  • Backed by Apollo Health Ventures
  • Selective therapeutics focus

Investors

NameLocationTypeStagesPortfolio
Apollo Health VenturesDusseldorf, Germany / Boston, USAbiotech-focused
seedseries-a+1
15